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Introduction
e feel that ongoing discourse between mental
health clinicians and neuroscientists is beneficial both
for scientific progress in neuroscience and mental health
treatments. Neuroscientists may benefit from being edu-
cated about clinical models of mental disorders and
advances in the nosography of these disorders. The
reductionist approach intrinsic to scientific activity forces
neuroscientists to simplify their models in the pursuit of
scientific questions considered to be of a fundamental
nature. Unavoidably, at times, this approach may ignore
some aspects of mental disorders. A discourse with clin-
icians allows neuroscientists to realign their models to
ensure that they represent processes thought to cause or
maintain these disorders. 
Benefits to clinicians involve being informed of new
research findings that have the potential to be applied in
new pharmacological and nonpharmacological treat-
ments. We provide two examples of how findings on
memory, ie, reconsolidation and forgetting, may provide
the impetus for new treatment interventions for several
mental disorders. More generally, we believe that an elu-
cidation of the memory processes not only provides clin-
icians with a list of potential clinical phenomena that
could be the target of interventions, but it can also per-
mit an understanding of why some kinds of treatments
are more efficacious than others. In addition, our under-
standing of the memory processes can provide significant
contribution to the refinement of extant psychotherapies,
including cognitive behavioral therapy (CBT). 
The aim of this review is to advocate how an under-
standing of the brain mechanisms involved in memory
C l i n i c a l  r e s e a r c h
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This review aims to demonstrate how an understanding
of the brain mechanisms involved in memory provides a
basis for: (i) reconceptualizing some mental disorders; (ii)
refining existing therapeutic tools; and (iii) designing
new ones for targeting processes that maintain these dis-
orders. First, some of the stages which a memory under-
goes are defined, and the clinical relevance of an under-
standing of memory processing by the brain is discussed.
This is followed by a brief review of some of the clinical
studies that have targeted memory processes. Finally,
some new insights provided by the field of neuroscience
with implications for conceptualizing mental disorders
are presented. 
© 2013, AICH – Servier Research Group Dialogues Clin Neurosci. 2013;15:475-486.
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provides a basis for: (i) re-conceptualizing some of the
mental disorders; (ii) refining existing therapeutic tools;
and (iii) designing new ones for targeting processes that
maintain these disorders. We start by defining some of
the stages which a memory undergoes and discuss why
an understanding of memory processing by the brain has
clinical relevance. We then briefly review some of the
clinical studies that have targeted memory processes. We
end by discussing some new insights from the field of
neuroscience that have implications for conceptualizing
mental disorders.
Defining memory phases
Forgetting
As Ebbinghaus1 demonstrated in his classic work, new
memories can do one of two things; persist or be forgot-
ten (Figure 1). It is generally assumed that forgetting is
more a vice (ie, dysfunction) than a virtue (ie, constitu-
tive process). However, the idea that forgetting might be
beneficial for memory has been frequently expressed.2-6
In the literary world, Jorge Luis Borges illustrated the
essential role of forgetting for the human experience in
his short story about Funes.7 As Funes could not forget
anything, he could not live a normal life because a sea of
unimportant details swamped every moment of aware-
ness. We agree that, without constitutive forgetting, effi-
cient memory would not be possible in the first place. 
Forgetting of established long-term memory (LTM) may
indicate that memory is either physically unavailable (ie,
lost), or that it is (temporarily) inaccessible. With some
exceptions, theories proposed within the domains of
experimental and cognitive psychology often emphasize
one type of forgetting over the other.8 Two explanations
for actual, nonpathological forgetting have been pro-
posed; one involving decay of aspects of the memory
trace, the other involving interference with it.9,10 Current
consensus favors the latter of these two explanations for
actual forgetting. 
Notwithstanding the success of interference-based theo-
ries to describe the factors that promote forgetting, the
truth is we do not know why or how the brain actually
forgets.11,12 Recently, Hardt and colleagues have proposed
a model of forgetting at both the cellular and systems
level, and put forward a neurobiologically based frame-
work for memory and forgetting.13 One inspiration for this
framework is recent advances in the study of the cellu-
lar/molecular underpinnings of LTM persistence suggest-
ing that memory decay is a major forgetting process.
One reason for this transition, in view of the nature of for-
getting, is the finding that forgetting engages neurobio-
logical mechanisms in the brain. In fact, the mechanisms
implicated in forgetting overlap with the mechanisms
implicated in learning and memory. For example, learning
and memory have been suggested to be mediated by a
nuanced neurobiological process that is initiated by cal-
cium signaling from the N-methyl-D-aspartate (NMDA)
receptor.14 At the cellular level, learning has been pro-
posed to enhance the synaptic efficacy leading to long-
term potentiation (LTP).15 The main hypothesis of the
neurobiological instantiation of LTM is an increase in the
number of: (i) presynaptic vesicles that are released16; (ii)
post-synaptic receptors17; or (iii) synapse number.18 The
post-synaptic receptors associated with LTM are thought
to be actively maintained by a constitutive kinase called
protein kinase zeta (PKM ) as well as other putative
memory maintenance molecules.19
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Figure 1. The forgetting curve. Herrmann Ebbinghaus famously conducted
all experiments described in his seminal monograph “On
Memory” with himself as the only subject. The data plotted in this
curve are taken from the table on p 103.1 It shows that the longer
the time between learning and relearning a set of nonsense sylla-
bles, the more the original learning was forgotten. Importantly,
most of the material was forgotten shortly after acquisition, fol-
lowed by a reduction of curve acceleration . This type of relation-
ship has been replicated in many species and for many different
types of memories, and this research overall suggested that mem-
ory retention (R) over time can be described with an exponential
function and negative acceleration (see inset). Despite significant
research efforts, the neurobiological processes that underpin the
forgetting function have not yet been described. R, memory reten-
tion; s, relative strength of memory; t, time
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Forgetting can be prevented by NMDA receptor antag-
onists, which reverse the putative LTP induced by learn-
ing. These findings suggest that a core process involved
in LTM maintenance prevents the internalization of
receptors associated with forgetting. Since memory
strength can increase with synaptic receptor expression,20
forgetting may reflect the loss of the physical instantia-
tion of the memory from relevant synapses. Thus, for-
getting likely presents a biologically active process,
rather than a shortcoming or failure of memory.13
Consolidation
There have been three lines of evidence to support the
existence of a stabilization period of the order of hours
after the acquisition of new memories. First, performance
can be impaired if amnesic treatments such as electro-
convulsive shock21 or protein synthesis inhibitors22 are
administered after learning. Second, performance can be
impaired if new competing learning occurs after the ini-
tial learning.23 Third, retention can be enhanced by admin-
istration of various compounds, such as strychnine, after
the initial learning.24 Critically, all three manipulations are
effective only when given shortly after new learning, not
when given after a delay. These findings gave rise to the-
ories of synaptic consolidation (Figure 2A).25-27
The initial unstable trace is called “short-term memory”
(STM), with a duration of the order of hours. With time
the trace enters LTM, at which point it is considered to
be consolidated and can no longer be affected by treat-
ments such as those listed above. Thus, if a memory is
susceptible to enhancement or impairment, it is consid-
ered to be in a labile, nonconsolidated state, and if it is
insensitive to administration of these amnesic treatments
then the memory is, by definition, consolidated.26,28 Once
a memory has become consolidated it remains in the
fixed state and should be forever insensitive to future
amnesic treatments.26
Reconsolidation
Research on reconsolidation as another time-dependent
restabilization processes was rediscovered with a paper
by Nader and colleagues who demonstrated reconsoli-
dation in a well-defined behavioral protocol (ie, auditory
fear conditioning in the rat).29 Targeting directly the
brain circuitry that is critical in mediating behavior and
its consolidation (ie, basolateral nucleus of the amyg-
dala), and using a drug with well-documented amnesic
effects on memory consolidation (ie, inhibition of pro-
tein synthesis with the antibiotic anisomycin), the
authors showed that reminders could bring well-consol-
idated fear memories back to an unstable state; while in
this state, these reactivated memories could be disrupted
by inhibiting protein synthesis in the basolateral amyg-
dala. Using the conceptual framework of the field of
consolidation, the authors concluded that consolidated,
but reactivated, memories return to an unstable state
from which they must restabilize in order to persist
(Figure 2B).30
Since publication of this study, reconsolidation has been
demonstrated with a range of species, tasks, and amnesic
agents. The extant evidence for the existence of a recon-
solidation process is once again based on the same three
lines of evidence on which consolidation theory is
rooted. First, performance can be impaired if amnesic
treatments such as targeted infusions of protein synthe-
sis inhibitors are given shortly after reactivation.29,31,32
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Figure 2. Principal properties of consolidation and reconsolidation. A) A
textbook account of consolidation. New memories exist in an
unstable state, during which their retention can be either
enhanced or impaired. Over the next few hours memories are
stabilized/consolidated over time into long-term memories, and
once in that state, they remain fixed or permanent. B) A model
of memory that incorporates the findings of consolidation and
reconsolidation (proposed by Lewis, 1979). New and reactivated
memories are in an active/unstable state and stabilize over time
into an inactive memory state. Remembering may return inac-
tive memories to an active state during which they can be
enhanced or impaired again by similar pharmacological or
behavioral intervention. 
Adapted from ref 10: Lewis DJ. Psychobiology of active and inactive
memory. Psychol Bull. 1979;86:1054-1083. Copyright © American
Psychological Association 1979
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Second, performance can be impaired if new competing
learning occurs in short temporal proximity to reactiva-
tion.33 Third, retention can be enhanced by the admin-
istration of various compounds, such as activators of sig-
naling pathways, important for consolidation after
reactivation of the memory.34 At the cellular and molec-
ular level, a number of studies have demonstrated that
blockade of reconsolidation of LTM leads to a reversal
of molecular correlates of that LTM.35-37
A study by Lee demonstrated that neurons use consoli-
dation mechanisms the first time a memory is acquired.
For subsequent modification of the memory, including
strengthening of the memory, neurons engage reconsol-
idation to stabilize the strengthening of the memory.38,39
One implication from this study is that memories rely on
reconsolidation mechanisms throughout their lifetime.
The brain engages consolidation mechanisms only dur-
ing the initial memory storage. 
Memory impairments induced by blocking reconsolida-
tion can be relatively memory-specific. Indeed, only
reactivated memories will be impaired.40 From a thera-
peutic perspective, this means that when a patient is
asked to recall, for example, a traumatic memory and
then given an reconsolidation blockage agent, only that
memory and not others will be blocked from being
reconsolidated (ie, restabilized). While most of the ther-
apeutic tools at the psychiatrist’s disposal may have
wide-ranging effects, the ability to target one memory at
a time should be very good news for the field. 
Clinical implications of reconsolidation
Why should clinicians care about the mechanisms medi-
ating memory stabilization? As basic research scientists
we need to explain how an understanding of the mech-
anisms of memory storage may shed light on the
processes that maintain several mental disorders.
The fact is that memory phases and mechanisms are
thought to be common for synapses representing a
memory, the dysfunctional synapses that contribute to
many disorders.14 The finding that consolidated memo-
ries return to a labile state and have to be restored has
significant implications for a number of clinical condi-
tions such as post-traumatic stress disorder (PTSD),
addiction, obsessive-compulsive disorder (OCD), or
delusions/hallucinations. An understanding of the mech-
anisms mediating reconsolidation could provide the
basis for developing new or refining old therapeutic
tools to successfully manage, if not cure, some of these
conditions. As an example of how this could be applied,
imagine a patient with PTSD whose symptoms were
resistant to both drugs and psychotherapy. A new way of
treating this condition could be to reactivate the
patient’s traumatic memory and block its reconsolida-
tion. Theoretically, this should lead to a “cure” within a
single session. Although finding a cure in the removal of
a memory in a single session may sound worthy of fic-
tion, early studies on humans using electroconvulsive
therapy (ECT) demonstrates that this possibility may
not be incompatible with real life.
Franks and colleagues41,42 treated patients suffering from
either hallucinations, delusions, major depression, or
OCD. In contrast to other studies that administered
ECT when the subjects were anesthetized, Rubin and
colleagues kept the patients awake and directed them
to focus on the objects of their compulsions or halluci-
nations. This experimental procedure reactivated the
neural mechanisms mediating those memories when the
ECT was delivered. All of the subjects were reportedly
“cured” of their condition, even though some had had
up to 30 previous ECT treatments while under anes-
thesia. The majority remained symptom-free for the 2-
year period between the treatment and the publication
of the manuscript. The fact that ECT was effective only
when the memories were reactivated, but not when the
memory reactivation was omitted (ie, when the patient
was anesthetized), suggests in principle that reconsoli-
dation occurs in humans. Furthermore, this study pro-
vides evidence that the possibility of curing someone by
removing a memory in a single session may not be so
remote. 
Current treatments for PTSD 
and their possible limitations
Current psychological treatments of PTSD target mech-
anisms called extinction (Figure 3). After learning has
occurred, the presentation of the conditioned stimulus
(CS) elicits conditioned responses. Within the context of
life-threatening situations, such as a car accident, the per-
son learns to associate a certain stimulus with the possi-
bility of death. Over time, any stimulus similar to the
original stimulus (eg, a backfire of a car) can trigger the
fear memory acquired during the exposure to the life-
threatening situation. The person is again overcome with
the traumatic experience of reliving the threatening sit-
C l i n i c a l  r e s e a r c h
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uation, a process that is mediated by the amygdala.43-45 To
learn that the new stimulus (ie, the backfire of a car) no
longer announces death, the person should be exposed
to the same stimulus in a safe environment over and
over again. This procedure is referred to in the literature
as “extinction learning.” 46 With time, the person will stop
experiencing fear because the person has now learned
that the stimulus no longer means threat or danger. 
However, since Pavlov, we have known that the expec-
tation of threat is not lost, but that the fear upon being
exposed to the stimulus is simply inhibited.46,47 We also
now know that extinction learning is not nearly as robust
as the initial learning to fear the stimulus. As such, the
fear reaction can return any time, and often does within
a few hours or days.46,47 In addition, if a similar stimulus
is subsequently experienced in a new environment, the
original fear can return.46,47 These properties of extinc-
tion learning may explain why treatments such as CBT
for PTSD, which mostly rely on extinction learning as
therapeutic intervention, have only limited effectiveness.
Extinction learning cannot inhibit the activation of these
traumatic memories for long periods of time, and the
benefits observed in the therapist’s office may not gen-
eralize to other contexts (Figure 4). 
Given that extinction is not as strong a process as the
traumatic memory, other neuroscientists proposed a
modification that could make extinction learning more
robust. The key to the method is the activation of the
NMDA receptors with partial agonists such as d-cyclo-
serine (DCS), which was found to enhance extinction
learning.48,49 Davis and his colleagues suggested how
DCS given prior to extinction of trauma should enhance
the effect of CBT for PTSD.50
Our concern with this revised extinction learning pro-
cedure is that a significant number of trials should be
administered in order for DCS to enhance extinction of
traumatic memory. If an insufficient number of extinc-
tion trials are administered, the memory will undergo
reconsolidation. The effect of DCS on the fear memory
when it undergoes reconsolidation is the enhancement
of the fear memory (Figure 5).51 The only way to know
Memory as a new therapeutic target - Nader Dialogues in Clinical Neuroscience - Vol 15 . No. 4 . 2013
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Figure 3. Schematic of learning and extinction processes. A) In condi-
tioning, an association is learned between a conditioned stimu-
lus (CS) and an unconditioned stimulus (US). CS and US can be
of largely any modality; for example, a tone and a foot-shock.
This learning will result in a conditioned fear response. B)
Extinction was first reported by Pavlov. Extinction is considered
new learning that inhibits the expression of the memory. It is
much weaker than conditioning and results in a reduced condi-
tioned response. For example, only one pairing of a tone and
shock can lead to conditioned fear responses over the duration
of an animal’s life. Extinction takes many trials over time to
reduce performance, and the reduction is rarely complete.  
Adapted from ref 108: Bouton ME, Nelson JB. Context-specificity of
target versus feature inhibition in a feature-negative discrimination. J
Exp Psychol Anim Behav Process. 1994;20:51-65. Copyright ©
American Psychological Association 1994
A. Learning
CS US
US
Context
time
CS
B. Extinction
Figure 4. Schematic of extinction learning. Extinction trials entail present-
ing the conditioned stimulus (CS) in the absence of the uncon-
ditioned stimulus (US). With each CS presentation, the condi-
tioned response is reduced as new learning occurs (CS no longer
predicts the US). In animal studies, extinction always takes many
more trials to inhibit performance that those required for its
acquisition. The strength of extinction is typically reduced with
time once an animal is removed from the extinction context. The
amount of inhibition of the original memory decreases and the
conditioned response is observed. This phenomenon is called
spontaneous recovery (test A). Extinction learning is also reduced
when animals are tested in a different context from the one in
which they received extinction training (test B). This property is
called renewal.  There is no metric for how many extinction ses-
sions are required for a certain percentage of responding. 
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whether the memory has been extinguished is to admin-
ister real-time measures of fear levels during CBT. As
most clinicians will not administer any measurement
during treatments they may not know whether the mem-
ory has been extinguished enough to facilitate extinction.
Based on the rodent studies, if not enough fear extinc-
tion learning has occurred DCS will make the traumatic
memory stronger. Consistent with this hypothesis, a
recent study in patients with generalized social anxiety
reported that only those patients whose fear was low fol-
lowing the in-session exposure (significant fear extinc-
tion) benefited from DCS relative to those in the
placebo condition (ie, no DCS but only exposure). In
contrast, those patients in the DCS condition who
reported high levels of fear (minimal fear extinction) fol-
lowing exposure were found to experience less clinical
improvement than patients in the placebo condition.52
What may further complicate the treatment of PTSD
patients (Figure 6) is that their neurobiology is in a state
where the administration of the DCS plus CBT will lead
to the strengthening of their traumatic memory.
Specifically, it has been known for some time that the
brain areas associated with extinction are thought to be
compromised in PTSD patients.53 Indeed, a recent study
by Milad and colleagues demonstrates that fear extinc-
tion learning was impaired in PTSD subjects.54 The
inability to extinguish fear memories is considered a core
component of PTSD. Consequently, treatments that rely
on the facilitation of extinction learning cannot easily
take place because the brains of PTSD subjects do not
acquire extinction. In the absence of extinction, CBT
should induce reconsolidation, which in the presence of
DCS should make the traumatic memory stronger. Two
recent reports testing the effects of DCS on CBT found
either no facilitation or reduction of the efficacy of CBT
in PTSD consistent with our concerns outlined.55,56 Thus,
for mental conditions that can undergo extinction learn-
ing, facilitated extinction may be a logical and exciting
intervention tool. However, in the case of PTSD patients
who do not show extinction, as there is nothing to facil-
itate, this tool may not be optimal. 
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Figure 5. A schematic of the findings of Lee et al.51 If a fear memory is
given enough extinction sessions to significantly reduce perfor-
mance as shown in green, then D-cyclo-serine (DCS), a N-
methyl-D-aspartate (NMDA) partial agonist can enhance extinc-
tion learning. In this case more than five extinction trials must
be given to engage extinctions mechanisms before it can be
enhanced. However, Lee also reported that DCS has the oppo-
site effect if the number of trials does not induce significant
extinction and the brain remains in a reconsolidation mode; the
fear memory is enhanced. The number of trials required for the
neurobiology to shift from reconsolidation to extinction mode is
an empirical question for each memory and individual. 
Adapted from ref 51: Lee JL, Gardner RJ, Butler VJ, Everitt BJ. D-
cycloserine potentiates the reconsolidation of cocaine-associated mem-
ories. Learn Mem. 2009;16:82-85.
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Figure 6. A schematic of why D-cyclo-serine (DCS) and cognitive behav-
ioral therapy (CBT) should lead to stronger traumatic memo-
ries instead of facilitated extinction in PTSD patients. For com-
mon people with regular fears, CBT sessions will eventually shift
the brain mechanisms from reconsolidation to extinction. If DCS
is administered after extinction mechanisms are engaged, then
the effectiveness of CBT should be enhanced. One of the defin-
ing features of PTSD is that patients are unable to extinguish fear
memories. Thus, regardless of how many sessions of CBT are
administered, the brain remains in reconsolidation mode, in
which case DCS will not facilitate extinction, but rather enhance
their traumatic memories. 
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Refining targets in the clinical population: 
the case of PTSD 
PTSD is more than too much fear. Criteria for PTSD in
the fifth edition of the Diagnostic and Statistical Manual
of Mental Disorders (DSM-5) acknowledge that fear is
only one component of PTSD, and that its symptoms
extend to a dysregulation of a variety of emotional
states, including anger, guilt, and shame.57-60 Two path-
ways of emotion dysregulation, defined here as collec-
tively referring to disturbances in a variety of emotional
states, have been proposed in PTSD; one predominantly
associated with adult-onset trauma, and the other
related to repeated early life trauma.61 The first pathway
suggests that mechanisms of fear conditioning and stress
sensitization and kindling underlie emotion dysregula-
tion experienced as a result of adult-onset trauma.
Repeated sensitization to trauma-related stimuli may
lead not only to a generalization of the fear response, but
also to dysregulation of various emotional states through
mechanisms comparable to kindling, which is a process
that involves the development of generalized seizures
following repeated, subthreshold electrophysiological
stimulation. The intensification and broadening of emo-
tional symptoms over time often observed in individu-
als with PTSD may be related to the original fear
response becoming increasingly sensitized, thereby
recruiting neighboring emotional circuits other than
those involved in fear.62-64 In contrast, the second path-
way focuses on the role of early developmental
processes, including disruptions in the caregiver/infant
attachment relationship, and early-life adversity in the
development of emotion regulatory systems.65 Such
experiences may lead to an abnormal development of
emotion regulatory capacities and thus reduce the effec-
tive regulation of fear arising from threatening or trau-
matic events. The latter can increase the risk of devel-
oping PTSD after trauma exposure later in life. These
differential pathways to emotion regulation lead to the
question of whether and how reconsolidation of trau-
matic memories may be affected by early-life experience.
Future research examining the effects of early life adver-
sity on processes of reconsolidation should therefore be
carried out in both animal and human studies. 
In the ideal case, altering the impact of the traumatic
memory by reconsolidation blockade would result in
restoring a patient’s quality of life. However, other affec-
tive and social cognitive disturbances can remain, even
after successful treatment of core PTSD symptoms. A
model proposing a social, cognitive, and affective neu-
roscience approach to PTSD which stresses the impor-
tance of assessing and treating not only PTSD symp-
toms, including traumatic memories per se, but also
dysfunction in the domains of emotion regulation and
interpersonal functioning, has been described.66 In this
regard, it is interesting to note that negative affect regu-
lation and interpersonal problems accounted for a
greater percentage of variance in functional outcomes
than did PTSD symptoms in a sample of women with
histories of childhood abuse.67 In addition, cognitive
deficits, including problems with executive functioning,
and processing speed, as well as learning and memory,
have been associated with PTSD.68,69 Future studies
examining the effects of reconsolidation blockade in
PTSD should therefore consider taking a broader assess-
ment of outcome, including impairments in cognition,
emotion regulation, and social cognition. The residual
distance to normal reintroduction to society could be
treated by CBT focusing on these additional domains.
Can propranolol change the course of 
PTSD when it targets consolidation of the
traumatic experience?
The effects of propranolol have been examined in
patients with a history of both acute traumatic experi-
ences and chronic PTSD. With regard to acute traumatic
experiences, in the first study examining the effects of
propranolol following an acute traumatic event, Pitman
and colleagues70 recruited 41 patients who exhibited a
pulse rate of ≥80 beats per minute from an emergency
room (ER). Patients were randomized to receive either
40 mg of propranolol or placebo, first administered
within 6 hours following the traumatic event during the
putative time during which the memory is consolidated,
and then for 10 days followed by tapering of the drug
over 9 days. Results showed that 1 month following the
traumatic event, individuals who had received propra-
nolol exhibited a statistically nonsignificant trend
towards lower Clinician Administered PTSD Scale
(CAPS) scores and reduced physiologic responding as
compared with the placebo group. A nonrandomized
control study by Vaiva and colleagues71 examined 19
acute trauma patients with a pulse rate of ≥ 90 beats per
minute recruited from an ER. Individuals were offered
40 mg of propranolol three times per day for 7 days, and
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PTSD symptomatology was compared in eight patients
who agreed to take propranolol with 11 patients who
declined the drug. Two months after the traumatic event,
PTSD rates and symptoms were lower in the group who
had received propranolol as compared with the group
who had chosen not to take propranolol. Furthermore,
a double-blind randomized controlled trial compared
the effects of propranolol, gabapentin, or placebo in indi-
viduals admitted to a level 1 surgical trauma center.
Propranolol was administered within 48 hours for a
period of 14 days, including uptitration for 2 days at 60
mg daily, acute treatment 120 mg daily for 8 days, and
tapering for 4 days.72 At 1- and 4-month follow-up, nei-
ther propranolol nor gabapentin led to superior out-
comes in terms of PTSD and depressive symptoms. In
the most recent randomized placebo-controlled study
examining the effects of propranolol in 41 acutely trau-
matized individuals recruited from an ER, Hoge and col-
leagues73 demonstrated no significant effect of up to 240
mg/day of propranolol administered for 19 days on
PTSD symptoms assessed at 1 and 3 months post-
trauma. However, in a subgroup of participants who
exhibited high drug adherence, physiological reactivity
during traumatic memory recall was significantly
reduced 5 weeks post-trauma in individuals who had
received propranolol as compared with placebo. 
Can propranolol change the course of 
PTSD when it targets reconsolidation 
of the traumatic memory?
In patients with chronic PTSD, three open-label trials
(n=28; n=7; n=32) have demonstrated that the adminis-
tration of propranolol combined with reactivation of the
traumatic memory led to a reduction in PTSD symptom
severity by 50% to 56% and a decline in the rate of
PTSD diagnosis of 71% to 86%.74 Similar results were
reported by Menzies in a study of 36 chronic PTSD
cases75 and an open-label trial by Poundja and col-
leagues.76 However, placebo-controlled randomized con-
trol trials will need to confirm these results. Additionally,
Brunet and colleagues77 examined physiological
responses in individuals with chronic PTSD in response
to administration of propranolol or placebo subsequent
to traumatic memory reactivation. Results demonstrated
decreased physiological response to later traumatic
memory recall with propranolol but not placebo. A strik-
ing finding in these studies is that a single reactivation
session was sufficient to induce reconsolidation in mem-
ories that were 30 years old. 
In summary, even though data suggest that propranolol
can reduce psychophysiological response associated with
both recent and remote traumatic memories, its effect in
PTSD symptoms per se, including reliving of the trau-
matic memory, avoidance symptoms, and emotional
numbing, still requires further investigation. One of the
core features of PTSD is that the traumatic memories
are often reexperienced in the form of sensory flash-
backs and are therefore not remembered but relived.78,79
To the best of our knowledge, no studies have investi-
gated if the effects of propranolol extend beyond phys-
iological effects, ie, altering the nature of how traumatic
memories are recalled. Future studies examining the
direct effect of propranolol on autobiographical mem-
ory recall are therefore warranted. Autobiographical
memory recall has been suggested to play a key role in
the experience of a continuous sense of self across time,
and activation of the default mode network may be
underlying this process since it has been shown to be
active when individuals are engaged in internally
focused or self-referential tasks, including autobio-
graphical memory retrieval, envisioning the future, and
theory of mind.80 Patients with PTSD have been shown
to have alterations in self-referential processing, includ-
ing autobiographical memory recall,81,82 future-oriented
thinking,83 and theory of mind.84,85 Moreover, default
mode network functioning which has been proposed to
be the underlying mechanism of these interrelated
processes has been shown to be altered in PTSD.86-88 The
relationship between self-referential processing, in par-
ticular autobiographical memory recall, the default
mode network, and brain networks involved in memory
reconsolidation will therefore be an important avenue
of future research. 
Can reconsolidation blockade affect other mental 
disorders? 
Substance addiction is a progressive psychopathology
that leads to compulsive substance-taking behavior.
Even after long periods of abstinence, relapse is quite
common.89 Cues in the environment that have acquired
an associative relationship with substances are thought
to contribute to substance taking and relapse.90 There are
at least two properties of cues associated with substances
that could contribute to substance-taking behavior. First,
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they can acquire rewarding and reinforcing properties
unto themselves,91 Second, they can induce the resump-
tion of substance-taking behavior (relapse).92,93 These
cue-substance associations are very persistent and resis-
tant to the extinction protocols used to decrease the
strength of these conditioned responses in humans94,95 or
animals.96 Thus, in the clinic, extinction-based treatments
have, to date, not been very effective. 
Craving is also thought to be a process that mediates the
effect of substance-related cues on relapse.97,98 Animal
models of drug addiction have reported that the neuro-
biological mechanisms of craving undergo reconsolida-
tion. When blocked, craving can reduce the ability of
substance-related cues to induce relapse.99 To date, tar-
geting craving via reconsolidation blockage has shown
to be the only short-term effective treatment (ie, one-
time intervention) of relapse-prevention. Consequently,
targeting reconsolidation of the mechanisms that medi-
ate drug craving should increase the likelihood of long-
term abstinence in humans.90
Two elegant studies have reported the effects of target-
ing reconsolidation on craving mechanisms in opiate-100
or cocaine-101 dependent drug users with amazing suc-
cess. Using a behavioral procedure akin to interference,
Xue100 reported that craving in opiate addicts was
reduced when reconsolidation was blocked. Similarly,
propranolol decreased cocaine craving in addicts who
had used cocaine for more than 20 years.101 However,
the difference in craving was not long-lasting, as the
experimental and placebo levels of craving were not sta-
tistically different 1 week after the intervention. One
possibility for this absence of a difference is that pro-
pranolol impairment was transient. Another possibility,
suggested by a visual inspection of the graphical pre-
sentation of the effect (Figure 1), is that the propranolol-
induced impairment in craving is relatively constant.
Future research should examine whether reduction in
craving translates to a reduction in relapse rates and sub-
stance abuse. 
Implications of forgetting for clinical practice:
some speculative ideas
Constitutive forgetting may provide important func-
tional contributions to the hippocampus. For example,
the loss of hippocampus-dependent spatial and contex-
tual memory may be instrumental for generalization
effects and the development of schemas.102 On the other
hand, because systematic forgetting processes may con-
trol the life-time of memories, their deregulation could
lead to accelerated and even pathological forms of mem-
ory loss, as seen in senescence and some dementias, such
as Alzheimer’s disease (AD). In the latter, β-amyloid
causes increases in postsynaptic calcium, which promotes
internalization and altered trafficking of synaptic α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) and NMDA receptors, notably increased
AMPA removal by engaging pathways involved in
LTD.103 This suggests that forgetting processes as
described above may be involved in the pathology of
AD, and the accelerated forgetting of episodic content
typical for the disease might drive the autobiographical
impairment and eventual loss of a self-narrative.
It is thus possible that the eventual synapse loss and cell
death, which characterize the final stages of AD, are dri-
ven in part by forgetting processes that spiral out of con-
trol. Traditional views of AD assume that dementia is
the result of neuron death or dysfunction in the affected
areas. While provocative but possible, one explanation
for this condition is that uncontrolled forgetting maybe
be one of the mechanisms leading to cell dysfunction
and death. 
Therapeutic approaches could therefore target certain
steps in molecular pathways associated with forgetting,
and possibly at time points well before the devastating
stages of the disease manifest. Drugs that affect the
synaptic removal of AMPA receptors might prove effec-
tive in preventing steps that eventually lead to synapse
deterioration, as synapse stability critically depends on
the glutamate (GluA2) and AMPA receptors.104 In ani-
mal models, it has been shown that the peptide
GluA23Y, which competitively prevents internalization
of GluA2-dependent AMPA receptors, can prevent
long-term depression, a possible physiological model of
plasticity mechanisms involved in forgetting.37 Thus,
developing methods to delivering GluA23Y either tar-
geted to specific brain areas or systemically might slow
down the progression of synaptic loss and memory dete-
rioration.
Forgetting and psychotic dissociations
In light of the likely involvement of NMDARs in con-
stitutive forgetting processes, we speculate that inhibited
forgetting might contribute to the development of psy-
chotic symptoms. For example, ketamine, an NMDA
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antagonist, can induce psychotomimetic states in
humans and can worsen symptoms in patients with
schizophrenia.105 Additionally, animal models of psy-
chosis are based on NMDAR antagonism in the hip-
pocampus.106 It may be possible that with significantly
reduced constitutive forgetting that removes the vast
majority of random memories encoded during wake
states,13 the system approaches states resembling inten-
sified interference, in which memory formation is greatly
impaired, and which can lead to the loss of previously
established memory patterns. This could lead to disso-
ciative states as a consequence simply of the inability to
encode new experiences. 
Conclusion
Memory is a dynamic process. In so being, it provides
clinical targets for the treatment of mental disorders,
such as forgetting and reconsolidation. As our under-
standing of forgetting grows, there may be better tools
to target and to slow down forgetting in certain demen-
tias, such as Alzheimer’s disease. Reconsolidation has
basic implications for a wide variety of mental disorders,
not just PTSD.  The fact that reconsolidation can oper-
ate on extremely strong and old memories107 presents
extremely exciting therapeutic prospects. Thus, recon-
solidation can provide clinicians with a time window of
instability to modify the neural circuits mediating men-
tal illness. The advantage of this approach is that one
does not need to first identify the specific neuroscientific
bases for each mental disorder before designing a treat-
ment for it. As Rubin’s studies demonstrate, allowing
memory states to be expressed was sufficient to return
circuits mediating mental disorders to become “un-
stored.” There are many such tools available for block-
ing the restorage of reactivated memories, ranging from
behavioral to pharmacological methods. ❏
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La memoria como un nuevo blanco 
terapéutico
Esta revisión busca demostrar cómo una compren-
sión de los mecanismos cerebrales involucrados en
la memoria aportan las bases para: 1) reconcep-
tualizar algunos trastornos mentales, 2) perfeccio-
nar las herramientas terapéuticas existentes y 3)
diseñar nuevas terapias para los procesos clave
que sustentan estos trastornos. Primero se defi-
nen algunas de las fases que están a la base de la
memoria y se discute la relevancia clínica de la
comprensión de los procesos de memoria por el
cerebro. Luego se revisan brevemente algunos
estudios clínicos que se han enfocado en procesos
de memoria y finalmente se presentan algunas
nuevas perspectivas provenientes de las neuro-
ciencias que tienen repercusiones para la concep-
tualización de los trastornos mentales. 
La mémoire comme nouvelle cible 
thérapeutique
Cet article démontre comment la compréhension
des mécanismes cérébraux impliqués dans la
mémoire sert de base à : a) reconceptualiser cer-
tains troubles mentaux; b) améliorer les outils thé-
rapeutiques existants ; et c) élaborer de nouveaux
outils pour cibler les processus qui entretiennent ces
troubles. Nous définissons tout d’abord certains des
stades par lesquels passe la mémoire, et nous ana-
lysons la pertinence clinique du traitement de la
mémoire par le cerveau. Nous poursuivons par une
brève mise au point de quelques études cliniques
sur les processus mnésiques. Nous présentons enfin
les nouveautés dans le domaine des neurosciences
et leurs conséquences dans la conceptualisation des
troubles mentaux.
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